Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
2(66.7%)
Phase 4
1(33.3%)
3Total
Phase 2(2)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07570433Phase 4Not Yet Recruiting

HORUS-Cytomegalovirus Open Proof-of-concept Exploratory Trial

Role: lead

NCT07443709Phase 2Not Yet Recruiting

Zoster Vaccine to Enhance Protection Against Zoster in Solid-organ Transplantation

Role: lead

NCT03699839Phase 2Completed

Reducing the Burden of Influenza After Solid-Organ Transplantation

Role: lead

All 3 trials loaded